Skip to main content


BSF announced this week that Kate McCurdy has been appointed as the new Chair of the Board, effective April 1, 2020. Kate succeeds Susan McCormack who has led BSF since 2018. During the period that Susan was chair, BSF made significant strides in translational research and advocacy, most notably hosting the externally-led Patient-Focused Drug Development (PFDD) meeting with the FDA in 2018. In addition, BSF supported the launch of the first two clinical trials in Barth syndrome. “Kate is uniquely able to lead BSF in this next phase of our work to advance therapies for Barth syndrome," says Susan.

Many BSF families and supporters know Kate already, as she has been involved as a leader in multiple capacities at BSF since the beginning. Most recently, Kate has served on BSF's Board of Directors as the liaison to BSF's Scientific Medical & Advisory Board (SMAB).

Kate feels very honored to have this opportunity. “We are closer today than we have ever been before to a treatment for Barth syndrome. However, advancing potential therapies will require significant additional investment, new approaches, new partners and the continuing patience and engagement of our community. Nonetheless, in just 20 years BSF has achieved what many thought was impossible by advancing the scientific and medical understanding of Barth syndrome and laying the building blocks for what is still ahead. I am honored to continue to help drive this organization’s strategic efforts and am 100% committed to the shared vision to eradicate Barth syndrome.

Read the full press release here--> 

Powered by Firespring